Evaluation of Depression and Anxiety in Chemotherapy Patients
| Status: | Recruiting |
|---|---|
| Conditions: | Depression |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 89 |
| Updated: | 6/17/2018 |
| Start Date: | December 20, 2017 |
| End Date: | December 20, 2019 |
| Contact: | Dennis Bloomfield |
| Email: | dbloomfield@rumcsi.org |
| Phone: | 718-818-2707 |
This study will examine the existence and severity of depression and anxiety in patients
undergoing chemotherapy at RUMC. Patients currently undergoing initial chemotherapy cycle
will be compared to patients undergoing a subsequent chemotherapy cycle. Data will then be
collected using standardized depression and anxiety scales to assess if these comorbidities
exist and to what severity level. Data already collected for depression and anxiety in
patients with chronic, but not cancer, illness will be used as a control.
The participants will be screened for signs of psychological distress using three self
administered questionnaires: the Generalized Anxiety Disorder 7 item Scale (GAD7) and Patient
Health Questionnaire (PHQ9). Demographic information about the participants, including
medical and psychiatric history, will also be gathered from their medical records.
undergoing chemotherapy at RUMC. Patients currently undergoing initial chemotherapy cycle
will be compared to patients undergoing a subsequent chemotherapy cycle. Data will then be
collected using standardized depression and anxiety scales to assess if these comorbidities
exist and to what severity level. Data already collected for depression and anxiety in
patients with chronic, but not cancer, illness will be used as a control.
The participants will be screened for signs of psychological distress using three self
administered questionnaires: the Generalized Anxiety Disorder 7 item Scale (GAD7) and Patient
Health Questionnaire (PHQ9). Demographic information about the participants, including
medical and psychiatric history, will also be gathered from their medical records.
The purpose of the study is to see how common Anxiety, Depression and distress are in people
who are undergoing treatment for cancer. We want to understand how common these issues are in
order to better screen for, and treat people suffering from them. Past studies have shown
that people with anxiety or depression and cancer have worse outcomes, and a study evaluating
how common these issues are has not been done. Patients presenting for chemotherapy will be
identified and approached for participation by members of the research team. The purpose and
design of the study will be explained. After informed consent is obtained, the surveys will
be administered by the study team. Completing surveys will take 20 minuets. Relevant
demographic information will be collected from the patients EMR. Recruitment will extend over
one year period. Those determined to be suffering from anxiety or depression will be given
the option of psychiatric follow up or intervention.
who are undergoing treatment for cancer. We want to understand how common these issues are in
order to better screen for, and treat people suffering from them. Past studies have shown
that people with anxiety or depression and cancer have worse outcomes, and a study evaluating
how common these issues are has not been done. Patients presenting for chemotherapy will be
identified and approached for participation by members of the research team. The purpose and
design of the study will be explained. After informed consent is obtained, the surveys will
be administered by the study team. Completing surveys will take 20 minuets. Relevant
demographic information will be collected from the patients EMR. Recruitment will extend over
one year period. Those determined to be suffering from anxiety or depression will be given
the option of psychiatric follow up or intervention.
Inclusion Criteria:1)Patients (greater than equal to) 18 years of age 2)Patients with a
confirmed diagnosis of a solid tumor or hematologic cancer 3)Patients who are able to
understand the informed consent and read the selfadministered metrics. 4)Patients
undergoing chemotherapy.
Exclusion Criteria:
- Patients unable to give informed consent.
- Patients with a previous diagnosis of anxiety or depression prior to chemotherapy
We found this trial at
1
site
Staten Island, New York 10310
Principal Investigator: Dennis Bloomfield, MD
Phone: 718-818-2707
Click here to add this to my saved trials
